Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Actinium Pharmaceuticals Inc
(NY:
ATNM
)
1.820
-0.130 (-6.67%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Actinium Pharmaceuticals Inc
< Previous
1
2
3
Next >
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 18, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 09, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
August 07, 2024
From
The Schall Law Firm
Via
Business Wire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024
August 06, 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
August 06, 2024
Via
Benzinga
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
August 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Tumbles 950 Points; ISM Services PMI Surges In July
August 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
August 05, 2024
FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium...
Via
Benzinga
Exposures
Product Safety
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
August 05, 2024
Via
Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
July 11, 2024
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.
Via
InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
July 02, 2024
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline.
Via
InvestorPlace
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
June 18, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
Via
Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 18, 2024
Via
AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
June 17, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first...
Via
Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 17, 2024
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin...
Via
FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
June 17, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
June 10, 2024
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news
Via
InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
June 07, 2024
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.
Via
InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
May 14, 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.
Via
InvestorPlace
Exposures
Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
May 09, 2024
Via
AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
April 29, 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
April 19, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
April 17, 2024
Via
AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Via
InvestorPlace
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.